Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
51.56
-0.48 (-0.92%)
Nov 12, 2026, 4:00 PM EST - Market closed
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $224.56M in the quarter ending September 30, 2026, with 36.22% growth. This brings the company's total for the last twelve months to $651.04M, up 49.38% year-over-year. In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth. That makes Travere Therapeutics the 9,804th largest company in the world by revenue and 2,126th in the United States.
Revenue (ttm)
$651.04M
Revenue Growth
+49.38%
P/S Ratio
7.60
Revenue / Employee
$1,309,928
Employees
497
Market Cap
4.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -118.03M | -51.88% |
| Dec 31, 2021 | 227.49M | 29.17M | 14.71% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.16B |
| Ionis Pharmaceuticals | 960.09M |
| Tango Therapeutics | 53.81M |
| CRISPR Therapeutics AG | 25.17M |
| Dianthus Therapeutics | 2.72M |
| Scholar Rock Holding | 570.00K |
TVTX News
- 11 hours ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 1 day ago - Travere Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 2 days ago - Travere Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 6 days ago - Travere Therapeutics price target lowered to $86 from $90 at JPMorgan - TheFly
- 8 days ago - Travere Therapeutics price target lowered to $78 from $89 at Guggenheim - TheFly
- 8 days ago - Travere Therapeutics price target raised to $72 from $70 at Canaccord - TheFly
- 9 days ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 9 days ago - Buy Travere Therapeutics on weakness, says Cantor Fitzgerald - TheFly